Simpson Thacher represented Apax Partners LLP in connection with the financing of its acquisition of Neuraxpharm Arzneimittel GmbH (“Neuraxpharm”). The transaction is subject to customary closing conditions and is expected to close in the next few months.

Neuraxpharm is a leading German pharmaceutical company with a particular focus on generic pharmaceutical products for the treatment of disorders of the central nervous system.

The Simpson Thacher team included Ian Barratt, Kate Sinclair and Carys Hughes (Banking and Credit).